Is it possible to cure the symptoms of the overactive bladder in women?

Krhút, Jan; Martan, Alois; Zachoval, Roman; Hanuš, Tomáš; Horčička, L; Švabík, Kamil; Zvara, Peter

doi:10.1007/s11255-017-1777-6

Cited by 5 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OAB is a chronic condition that requires long-term treatment, with only a small proportion of patients able to discontinue the treatment due to symptom cessation. 64 Mirabegron seems to have a well-balanced efficacy:side effects ratio; therefore, adherence to mirabegron and treatment persistence should be significantly better than AChs. However, a recent systematic literature review of real-world data documented that 1-year persistence rates were 12%–25% and 32%–38% for antimuscarinic agents and mirabegron, respectively.…”

Section: Mirabegronmentioning

confidence: 99%

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Krhút¹,

Skugarevská²,

Míka³

et al. 2022

RRU

Self Cite

View full text Add to dashboard Cite

This nonsystematic review provides a summary of current evidence on the use of β 3 -adrenoreceptor agonists (β 3 -ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, β 3 -ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladder. Although it is widely believed that β 3 -ARAs cause detrusor relaxation, the effect on bladder afferent signaling likely plays an important role in their mechanism of action as well. In 2011 and 2012, mirabegron was approved for clinical use in overactive bladder (OAB) patients. Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. The only side effect showing significantly higher incidence than placebo was nasopharyngitis. Mirabegron is approved for OAB treatment in all age-groups and in pediatric patients with neurogenic bladder. Vibegron is another β 3 -ARA approved for OAB treatment in the US and Japan. Several large, multicenter, double-blind, randomized trials have documented statistically significant superiority of vibegron over placebo on all efficacy end points. Other β 3 -ARAs are being developed; however, to date none has been introduced to clinical use. All β 3 -ARAs provide efficacy similar to anticholinergics. They have a favorable safety profile and are well tolerated. Due to their different mechanisms of action, combination of β 3 -ARAs with anticholinergic compounds allows for increased efficacy.

show abstract

Section: Mirabegronmentioning

confidence: 99%

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Krhút¹,

Skugarevská²,

Míka³

et al. 2022

RRU

Self Cite

View full text Add to dashboard Cite

show abstract

“…Khrut et al assessed the viability of ceasing mirabegron treatment after symptoms had decreased in OAB patients (37). Patients with an Urgency Bother-Visual Analog Scale score of 50% or less were counseled to stop mirabegron treatment at the 18-month visit.…”

Section: Beta-3 Adrenergic Receptor Agonistmentioning

confidence: 99%

The Pharmacotherapy Time-to-Effect of Overactive Bladder Medications and Treatment Duration

Przydacz¹,

Chłosta²

2020

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

For Overactive Bladder (OAB) treatment, pharmacotherapy is currently deemed as a second option. However, in the current publications related to OAB, there is a significant research gap concerning the time-toeffect and duration of OAB pharmacotherapy. Such data is vital for effective and successful treatment of OAB, and hence, the study aimed to find information in this gap to assist healthcare providers in their daily activities in treating OAB. The study utilized the Web of Science databases, MEDLINE, Cochrane Library, and PubMed Central to find and collect the highest number of data. The literature review showed limited research concerning the time-to-effect and optimal treatment duration for OAB. However, based on the available data, it can be stated that the time-to-effect of OAB pharmacotherapy would be after seven days of the initial treatment. Besides, patients with OAB can be effectively treated for 6 to 12 months before the medications are stopped but patients need to be carefully educated about a risk of symptom reoccurrence and retreatment. Those who require further medications or have a higher risk of symptom reoccurrence may need lifetime pharmacotherapy or different treatment approaches. Further research is needed to focus on the time-to-effect during the first week of medication to accurately determine when first symptom reduction occurs, and carefully follow up for patients that show a positive response after the treatment has been ceased.

show abstract

Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?

et al. 2022

View full text Add to dashboard Cite

Is it possible to cure the symptoms of the overactive bladder in women?

Abstract: A small percentage of OAB patients were able to discontinue mirabegron due to symptom cessation.

Cited by 5 publications

References 22 publications

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

The Pharmacotherapy Time-to-Effect of Overactive Bladder Medications and Treatment Duration

Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?

Contact Info

Product

Resources

About